WILLIAM G WIERDA to Erlotinib Hydrochloride
This is a "connection" page, showing publications WILLIAM G WIERDA has written about Erlotinib Hydrochloride.
Connection Strength
0.140
-
A Pilot Phase II Study of Erlotinib for the Treatment of Patients with Relapsed/Refractory Acute Myeloid Leukemia. Acta Haematol. 2018; 140(1):30-39.
Score: 0.140
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.